Zum Inhalt springen
Home » New Study Published in JCO Precision Oncology Shows Myriad Genetics‘ Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer

New Study Published in JCO Precision Oncology Shows Myriad Genetics‘ Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer

Myriad’s Prolaris Test is the only biomarker test to quantify the benefits of adding androgen deprivation therapy to radiation therapy1

New Study Published in JCO Precision Oncology Shows Myriad Genetics‘ Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer